Tumor Hospital of Guangxi Medical University

Recent papers from Tumor Hospital of Guangxi Medical University

1. CACA guidelines for holistic integrative management of PET imagingHolistic Integrative Oncology · 2026
2. Benmelstobart With or Without Anlotinib After Chemoradiotherapy for Unresectable Non−Small Cell Lung CancerJAMA Oncology · 2026
3. All deaths follow recurrence, but not all recurrences are fatal: a retrospective cohort study of recurrence timing and survival after curative resection of hepatocellular carcinomaFrontiers in Oncology · 2026
4. Association between an improved positioning management strategy and non-incisional low back pain and sleep quality in patients undergoing modified radical mastectomy for breast cancer: a retrospective cohort studyFrontiers in Pain Research · 2026
5. Circulating osteocalcin and incident dementia in the UK Biobank: a prospective cohort and exploratory multi-omics analysisFrontiers in Aging Neuroscience · 2026
6. Public omics data reuse in gastric cancer: from discovery abundance to translational evidenceFrontiers in Oncology · 2026
7. Trastuzumab Rezetecan in ERBB2-Low Advanced Breast CancerJAMA · 2026
8. Host miR-140-5p Directly Targets IFIT2 and Enhances Replication of a Zoonotic Reassortant Swine H3N2 Influenza VirusMicroorganisms · 2026
9. Anbenitamab plus HB1801 for HER2-Positive Advanced Breast CancerNew England Journal of Medicine · 2026
10. Efficacy and Safety of Benmelstobart Plus Anlotinib in Advanced Endometrial Cancer: Results of a Multi‐Cohort, Phase II Study (ETER200)MedComm · 2026
11. First-line osimertinib with or without chemotherapy for EGFR-mutant advanced NSCLC in China: a cost-effectiveness analysisFuture Oncology · 2026
12. Genome-Wide DNA methylation profiling of tissue-plasma pairs identifies Novel cfDNA biomarkers for the diagnosis of gastric cancerPLoS Genetics · 2026
13. Efficient delivery of DMDD by an iron-engineered mesoporous organosilica nanoplatform reshapes the breast cancer immune microenvironment via autophagy activation and immune checkpoint modulationCancer Nanotechnology · 2026
14. Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trialThe Lancet · 2025
15. Neutrophil dysregulation in sepsis-induced acute lung injury: mechanistic framework and therapeutic targeting by natural productsFrontiers in Pharmacology · 2026
16. Immunotherapy and targeted therapy plus hepatic arterial infusion chemotherapy for HCC with portal vein tumor thrombosis (CHANCE2504): a nationwide target trial emulation studyClinical and Molecular Hepatology · 2026
17. Exploring the relationship between gut microbiota and pan-cancer: a meta-analysis of Mendelian randomization studiesScientific Reports · 2026
18. Artificial Intelligence, Multi-Omics, and Multimodal Integration in Precision Radiotherapy for Head and Neck Cancer: From Biological Insights to Treatment DecisionsBiomedicines · 2026
19. A Cohort Study on Efficacy and Safety of Treatment Modalities for Resectable Hepatocellular Carcinoma with Extrahepatic MetastasisiLiver · 2026
20. Efficacy and Safety of PD ‐1/ PD ‐ L1 Inhibitors Combined With Anti‐Angiogenic Tyrosine Kinase Inhibitors for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Systematic Review and Single‐Arm Meta‐AnalysisCancer Medicine · 2026